Program
CG-0416
A development code.
Its studies are mostly in Obesity, led by HongKong Curegene Innovation.
Furthest: phase 1, since Jul 9, 20261 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HongKong Curegene Innovation | 11 open or running | phase 1since Jul 9, 2026 | Jul 9, 2026 | Mar 2027phase 1 · NCT07724431 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 9, 2026First study: phase 1 study in OverweightFirst studyNCT07724431 · 64 planned · Australia
Ahead
- Mar 2027Primary completion: phase 1 study in OverweightNCT07724431
TargetBeta
THRB →read by rule
“CG-0416 is a novel selective, liver-directed thyroid hormone receptor beta (THR-β) agonist, given orally once daily.”study text, by rule · the study
Other programs on THRB
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| resmetiromrule | Madrigal Pharmaceuticals | phase 4 | 22 |
| KYLO-0603 | Sino Biopharmaceutical | phase 2 | 2 |
| KPC000154rule | kunming-pharmaceuticals-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07724431Overweight · Australia | 1 | Not yet recruiting | Mar 2027 | 64 |
How it is read
Names in the registry
- “CG-0416”, 1 entry
Codes read as this program: CG0416.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.